AAPL 154.88 +1.84 (+1.20%)MSFT 105.38 +0.38 (+0.36%)FB 130.65 -2.52 (-1.89%)ZNGA 3.95 +0.07 (+1.68%)NVDA 133.37 -0.29 (-0.22%)WBA 68.22 +0.16 (+0.24%)GOOG 1029.8 -7.78 (-0.75%)PIH 4.14 +0.25 (+6.43%)
AAPL 154.88 +1.84 (+1.20%)MSFT 105.38 +0.38 (+0.36%)FB 130.65 -2.52 (-1.89%)ZNGA 3.95 +0.07 (+1.68%)NVDA 133.37 -0.29 (-0.22%)WBA 68.22 +0.16 (+0.24%)GOOG 1029.8 -7.78 (-0.75%)PIH 4.14 +0.25 (+6.43%)

Balance Sheet ABUS Quote Arbutus Bio

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
CashAndCashEqui 167 23 54
ShortTermInvest 15 107 72
Cash 181 131 126
AccountReceivab 1 0 0
Inventories 0 0 0
DeferredIncomeT 0 0 0
OtherCurrentAss 0 0 0
TotalCurrentAss 184 133 129
PPE 13 18 25
AccumulatedDepr -10 -11 -13
NetPPE 3 7 12
EquityAndOtherI 10 13 13
Goodwill 163 24 24
IntangibleAsset 353 99 59
OtherLTAssets 0 0 0
TotalNonCurrent 528 143 108
TotalAssets 712 276 237
ShortTermDebt 0 0 0
AccountsPayable 3 3 2
TaxesPayable 0 0 0
AccruedLiabilit 6 6 9
DeferredRevenue 1 0 3
OtherCurrentLia 1 1 1
TotalCurrentLia 11 11 15
Debt 0 12 12
DeferredTaxesLi 146 41 17
DeferredRevenue 0 0 0
OtherLTLiabilit 7 9 11
TotalNonCurrent 154 62 40
TotalLiabilitie 165 73 55
CommonStock 0 0 0
AdditionalPaidI 864 904 919
RetainedEarning -267 -651 -738
AccumulatedOthe -50 -50 -48
TotalStockholde 548 203 182
TotalLiabilitie 712 276 237
Arbutus Biopharma Corporation income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Arbutus Biopharma Corporation FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.